Conclusions: This first-in-human study demonstrated that CCR2 PET/CT molecular imaging is feasible and can identify increased wall instability in individuals with AAAs, especially in those at higher risk of disease progression. This evidence concerns the gene CCR2 and achalasia-alacrima syndrome.